SCHEMBL1159161

SCHEMBL1159161

Cn1cc(-c2ccnc(Nc3cc4ccn(CCO)c(=O)c4c(NC(C)(C)C)n3)c2)cn1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SYK P43405 2/20 0.41
GSK3B P49841 12/20 0.41
DYRK1A Q13627 12/20 0.41
WNT1 P04628 9/20 0.41
BRD4 O60885 1/20 0.40
CREBBP Q92793 1/20 0.40
IRAK1 P51617 1/20 0.39
TTK P33981 2/20 0.39
MAP3K12 Q12852 1/20 0.36
ABL1 P00519 1/20 0.36
NTRK1 P04629 1/20 0.36
YES1 P07947 1/20 0.36
MAPK1 P28482 1/20 0.36
AURKB Q96GD4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158803 0.89 SYK (0.42) SYKGSK3BDYRK1AMAPK1
SCHEMBL1158878 0.88 SYK (0.39) SYKGSK3BDYRK1AWNT1BRD4
SCHEMBL1158715 0.88 SYK (0.41) SYK
SCHEMBL1158689 0.88 SYK (0.41) SYKABL1
SCHEMBL1158949 0.88 SYK (0.42) SYKGSK3BDYRK1AWNT1BRD4
SCHEMBL1159036 0.87 GRM2 (0.45) SYKGSK3BDYRK1AIRAK1MAPK1
SCHEMBL1158941 0.86 SYK (0.41) SYK
SCHEMBL1158980 0.86 GRM2 (0.44) SYKGSK3BDYRK1AWNT1
SCHEMBL1158393 0.84 SYK (0.42) SYKGSK3BABL1
SCHEMBL1158894 0.84 SYK (0.42) SYKGSK3BDYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN SYK 1/4885GSK3B 355/4885DYRK1A 1000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.